• V Compère, B Dureuil, B Bourret, S Torre, K Azhougagh, D Provost, B Rachet, R Gillet, M Rieu, and L Marpeau.
• Département d'anesthésie-réanimation chirurgicale et samu, centre hospitalier universitaire de Rouen, 1 rue de Germont, Rouen, France.
• Ann Fr Anesth Reanim. 2012 Dec 1;31(12):933-6.

IntroductionThe use of magnesium sulfate (MgSO(4)) has been advocated since 2000 in France in the management of eclampsia. The aim of this study was to determine the frequency of use of this treatment for eclampsia in a French department.Patients And MethodsAll patients obstetrical patients admitted to Critical Care Units of Seine-Maritime for eclampsia over a period of 7 years (2002-2008) were included. Obstetric data, the treatment used for eclampsia and pre-eclampsia and maternofetal complications were collected. The primary outcome parameter was the use of MgSO(4) in the secondary prevention of eclampsia.ResultsThirty-nine patients were included. Nineteen patients (48%) had eclampsia in prepartum, three (8%) in per-partum and 17 (44%) in post-partum periods. The use of MgSO(4) in the secondary prevention of eclampsia was observed in 92% of cases (36/39). Primary prevention was seen in 8% of cases. The duration of treatment was 2 days (1-7 days). The maternal and perinatal mortality was respectively 2.5 and 11%.ConclusionIn this study, the use of MgSO(4) in the secondary prevention is frequent. This result emphasizes the importance of the recommendations of learned societies in the homogenization of the management of rare but serious conditions such as eclampsia.Copyright © 2012. Published by Elsevier SAS.

28 keywords...

hide…